Cancer Clinical Trials

Breast

  • Alliance A011202 - A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

  • Alliance A011401 - Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer

  • Alliance A011502 - A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

  • RTOG 1304 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Digestive/Gastrointenstinal

  • Clinical Genomics CG001 - Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed with Colorectal Cancer

  • Halozyme HALO-109-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

  • RTOG 1112 - Randomized Phase I Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib in Hepatocellular Carcinoma

Genetics

  • ECOG-ACRIN EAY-131 - A Trial That Aims to Establish Whether Patients With Tumor Mutations, Amplifications Or Translocations in One of the Genetic Pathways of Interest Are Likely to Derive Clinical Benefit If Treated With Agents Targeting That Specific Pathway In A Single-Arm Design

Genitourinary

  • Alliance A031501 - Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) In Muscle Invasive And Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation

  • BMS CA209-914 - Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Patients with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Gynecologic

  • Roche YO39523 - A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered In Combination With Paclitaxel, Carboplatin, and Bevacizumab To Patients With Newly-Diagnosed Stage III Or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal

Head and Neck

  • Galera GTI-4419-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer

Hematologic/Blood

  • Pharmacyclics PCYC-1134M-CA - informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

Respiratory/Thoracic

  • Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

  • Alliance A211401 - Reducing Surgical Complications In Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes

  • Oncocyte PRO068 - A Study to Evaluate a Panel of Blood Biomarkers For Use In Patients Undergoing Evaluation For Lung Cancer, ONC-LN-04

  • OSE Immunotherapeutics OSE2101C301 - A Randomized Parallel Group Phase III Trial of OSE 2101 as 2nd Line After Prior Platinum-Based Chemotherapy Failure or as 3rd Line After Platinum-Failure and Checkpoint Inhibitor-Failure, Compared With Standard Treatment (Docetaxel or Pemetrexed) In HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable For Radiotherapy or Metastatic Non-Small-Cell Lung Cancer. (OSE2101C301)

  • Spiration HDE#H06002 S005 - Spiration®(IBV) Valve System Reloadable Deployment Catheter System (HUD#03-0127)

  • Wistar Institute 20171914 - Identification of Cancer Markers in Samples of Peripheral Blood

Skin

  • ECOG-ACRIN EA6134 - A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab At Progression vs. Ipilimumab + Nivolumab Followed By Dabrafenib + Trametinib At Progression in Patients With Advanced BRAFV600 Mutant Melanoma